Osilodrostat phosphate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for osilodrostat phosphate and what is the scope of freedom to operate?
Osilodrostat phosphate
is the generic ingredient in one branded drug marketed by Recordati Rare and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Osilodrostat phosphate has one hundred and thirty-five patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for osilodrostat phosphate
International Patents: | 135 |
US Patents: | 6 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 8 |
Patent Applications: | 7 |
DailyMed Link: | osilodrostat phosphate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for osilodrostat phosphate
Generic Entry Date for osilodrostat phosphate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for osilodrostat phosphate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2009506048 | ⤷ Try for Free | |
Canada | 2954393 | FORMES PHARMACEUTIQUES (PHARMACEUTICAL DOSAGE FORMS) | ⤷ Try for Free |
World Intellectual Property Organization (WIPO) | 2007024945 | ⤷ Try for Free | |
Taiwan | I707682 | ⤷ Try for Free | |
Tunisia | SN08082 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | ⤷ Try for Free |
South Korea | 20120116482 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT | ⤷ Try for Free |
Morocco | 33904 | استخدام عامل تغيير هرمونات الكظرية | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for osilodrostat phosphate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2523731 | PA2020512 | Lithuania | ⤷ Try for Free | PRODUCT NAME: OSILODROSTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ISKAITANT OSILODROSTATO DIHIDROFOSFATA; REGISTRATION NO/DATE: EU/1/19/1407 20200109 |
2523731 | 2020C/520 | Belgium | ⤷ Try for Free | PRODUCT NAME: OSILODROSTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN, INCLUSIEF OSILODROSTAT DIWATERSTOFFOSFAAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113 |
2523731 | SPC/GB20/034 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: OSILODROSTAT, OR OSILODROSTAT PHOSPHATE; REGISTERED: UK EU/1/19/1407/001(NI) 20200113; UK EU/1/19/1407/002(NI) 20200113; UK EU/1/19/1407/003(NI) 20200113; UK PLGB 15266/0029-0001 20200113; UK PLGB 15266/0030-0001 20200113; UK PLGB 15266/0031-0001 20200113 |
2523731 | CR 2020 00025 | Denmark | ⤷ Try for Free | PRODUCT NAME: OSILODROSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER OSILODROSTATDIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200113 |
2523731 | C202030030 | Spain | ⤷ Try for Free | PRODUCT NAME: OSILODROSTAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, INCLUIDO EL OSILODROSTAT DIHIDROGENO FOSFATO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1407; DATE OF AUTHORISATION: 20200109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1407; DATE OF FIRST AUTHORISATION IN EEA: 20200109 |
2523731 | PA2020512,C2523731 | Lithuania | ⤷ Try for Free | PRODUCT NAME: OSILODROSTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ISKAITANT OSILODROSTATO DIHIDROFOSFATA; REGISTRATION NO/DATE: EU/1/19/1407 20200109 |
2523731 | 2090024-7 | Sweden | ⤷ Try for Free | PRODUCT NAME: OSILODROSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING OSILODROSTAT DIHYDROGEN PHOSPHATE; REG. NO/DATE: EU/1/19/1407 20200113 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Osilodrostat Phosphate
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.